LGT Group Foundation’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$62M Buy
2,206,233
+216,923
+11% +$5.78M 0.76% 30
2025
Q4
$49.7M Buy
1,989,310
+4,173
+0.2% +$105K 0.54% 37
2025
Q3
$54M Buy
1,985,137
+423,419
+27% +$10.5M 0.62% 36
2025
Q2
$37.9M Buy
1,561,718
+28,317
+2% +$660K 0.47% 48
2025
Q1
$38.9M Buy
1,533,401
+616,655
+67% +$16.1M 0.54% 42
2024
Q4
$24.3M Buy
916,746
+151,309
+20% +$4.1M 0.38% 55
2024
Q3
$21.9M Buy
765,437
+22,562
+3% +$658K 0.36% 56
2024
Q2
$20.8M Buy
742,875
+18,274
+3% +$503K 0.33% 55
2024
Q1
$20.1M Buy
724,601
+40,655
+6% +$1.13M 0.47% 47
2023
Q4
$19.7M Sell
683,946
-48,375
-7% -$1.46M 0.43% 54
2023
Q3
$24.9M Sell
732,321
-32,502
-4% -$1.15M 0.61% 45
2023
Q2
$28.1M Buy
764,823
+14,205
+2% +$553K 0.68% 35
2023
Q1
$30.6M Buy
750,618
+6,100
+0.8% +$263K 0.88% 25
2022
Q4
$38.1M Buy
744,518
+204,971
+38% +$9.83M 1.19% 18
2022
Q3
$23.6M Sell
539,547
-185,497
-26% -$9.01M 0.92% 26
2022
Q2
$38M Buy
725,044
+136,280
+23% +$6.94M 1.16% 18
2022
Q1
$30.4M Buy
588,764
+166,991
+40% +$8.66M 0.71% 30
2021
Q4
$24.9M Buy
+421,773
New +$20.9M 0.64% 31

Other funds holding PFE

LGT Group Foundation's PFE Position: Q1 2026 in Review

LGT Group Foundation increased its Pfizer (PFE) stake by 11% in Q1 2026, buying an estimated $5.78M and bringing the position to 2,206,233 shares worth $62M. The position accounts for 0.76% of the portfolio, ranked #30.

LGT Group Foundation first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • LGT Group Foundation held 2,206,233 shares of Pfizer worth $62M as of Q1 2026.
  • LGT Group Foundation bought 216,923 Pfizer shares in Q1 2026, an estimated $5.78M.
  • Pfizer made up 0.76% of LGT Group Foundation's portfolio in Q1 2026, its #30 holding.
  • LGT Group Foundation first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on LGT Group Foundation's 13F filing for Q1 2026, filed 28 Apr 2026.